COMMUNIQUÉS West-GlobeNewswire

Algernon Pharmaceuticals Appoints Leading Inflammatory Bowel Disease Expert Dr. Walter Reinisch to Its Medical and Scientific Advisory Board
04/04/2019
VANCOUVER, British Columbia, April 04, 2019 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCB: BTHCF) (the “ Company ” or “ Algernon ”) a clinical stage pharmaceutical development [...]
Intercept to Present Results from the First Successful Phase 3 Trial in Patients with Liver Fibrosis Due to NASH at the International Liver Congress™ 2019
04/04/2019
Multiple additional abstracts evaluating obeticholic acid (OCA) for the treatment of patients with progressive non-viral liver diseases to be presented at the meeting NEW YORK, April 04, 2019 (GLOBE NEWSWIRE) -- [...]
Homology Medicines Announces FDA Clearance of Investigational New Drug Application for HMI-102 Gene Therapy Candidate for PKU
04/04/2019
- Phase 1/2 pheNIX Trial Would Represent First PKU Gene Therapy to Enter the Clinic - - Initial Clinical Data Expected by the End of 2019 - BEDFORD, Mass., April 04, 2019 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. ( [...]
ContraFect Announces Presentations at the 29th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)
04/04/2019
Vance G. Fowler, M.D., Professor of Medicine in the Division of Infectious Diseases, Duke University to Present New Data from the Exebacase Phase 2 Study YONKERS, New York, April 04, 2019 (GLOBE NEWSWIRE) -- ContraFect [...]
RedHill Biopharma to Present at Three Conferences in April
04/04/2019
TEL-AVIV, Israel and RALEIGH, N.C., April 04, 2019 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq: RDHL) (Tel-Aviv Stock Exchange: RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily [...]
InspireMD, Inc. Announces Pricing of $2.4 Million Public Offering of Common Stock
04/04/2019
TEL AVIV, Israel, April 04, 2019 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by the treatment of carotid artery [...]
Changes to the Management Board of AS Olainfarm
04/04/2019
JSC Olainfarm hereby informs about the following decisions taken by its Supervisory Council on April 01, 2019: To recall Inga Krūkle from the position of Board member of AS Olainfarm; Appoint Lauris Macijevskis to the [...]
Announcement regarding the election of the Chairperson and deputy of the Council of JSC Olainfarm
04/04/2019
On 1 st of April, a new Supervisory Council has been elected at the Extraordinary Shareholders' meeting of JSC Olainfarm for a term of five years. Appointed members of the Supervisory Council are Gundars Bērziņš, Jānis [...]
Oxurion NV announces full enrollment of its Phase 2 trial evaluating efficacy and safety of the combination of anti-PlGF (THR-317) and anti-VEGF (ranibizumab) for treatment of DME, ahead of schedule
04/04/2019
Leuven, Belgium, April 04, 2019 (GLOBE NEWSWIRE) -- Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company developing innovative treatments to preserve vision in patients with diabetic eye disease, announces [...]
Genfit: GENFIT Announces Upcoming Presentations on NASH, PBC and Diagnostics at the European Association for the Study of the Liver (EASL) International Liver Congress 2019
04/04/2019
GENFIT Announces Upcoming Presentations on NASH, PBC and Diagnostics at the European Association for the Study of the Liver (EASL) International Liver Congress 2019 Elafibranor Phase 2 data in PBC accepted for late- [...]
Genfit: GENFIT annonce la présentation de nouvelles données sur ses programmes NASH, PBC et Diagnostic au congrès EASL ILC 2019
04/04/2019
GENFIT annonce la présentation de nouvelles données sur ses programmes NASH, PBC et Diagnostic au congrès EASL ILC 2019 Données de Phase 2 pour elafibranor dans la PBC acceptées en « late breaker » pour une présentation [...]
Satya Abadi Pharma to distribute Acetium® lozenge in Indonesia
04/04/2019
Press release 4.4.2019 at 09.30 local time (EEST) Biohit Oyj and Satya Abadi Pharma have signed an agreement for the distribution of the Acetium lozenge in Indonesia. The effectiveness of Acetium® lozenge in smoking [...]
Oncology Venture obtains option to in-license the European rights to the FDA approved ixabepilone
04/04/2019
Press release Hørsholm, Denmark and Cambridge, MA, US, April 4, 2019 – Oncology Venture A/S (“OV” or the Company) today announced that the company has obtained an exclusive option to in-license the European rights to [...]
Biocartis Group NV: Biocartis announces publication of its 2018 annual report
04/04/2019
Biocartis announces publication of its 2018 annual report Mechelen, Belgium, 4 April 2019 - Biocartis Group NV (the 'Company' or 'Biocartis'), an innovative molecular diagnostics company (Euronext Brussels: BCART), [...]
Curetis: Study Data Presented at ECCMID 2019 Confirm Clinical Benefits of Unyvero Platform
04/04/2019
Growing body of evidence shows benefits of Unyvero for antibiotic stewardship 8 new reports on European studies presented by clinical researchers using Unyvero HPN, ITI, BCU and IAI Amsterdam, the Netherlands; San Diego [...]
Grant of Options and RSUs and PDMR Dealings
04/04/2019
LONDON, April 04, 2019 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) (Nasdaq:VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for [...]
Motif Bio to Present Iclaprim Data at ECCMID 2019
04/04/2019
NEW YORK, April 04, 2019 (GLOBE NEWSWIRE) -- Motif Bio plc (AIM/NASDAQ: MTFB), a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, announced today that four iclaprim abstracts have [...]
DBV Technologies Announces Pricing of $70.4 million (€62.7 million) Global Offering of Ordinary Shares, Including in the Form of American Depositary Shares
04/04/2019
Montrouge, France, April 4, 2019 DBV Technologies Announces Pricing of $70.4 million (€62.7 million) Global Offering of Ordinary Shares, Including in the Form of American Depositary Shares DBV Technologies (the “Company [...]
DBV Technologies annonce le prix de son offre globale d’actions ordinaires, pouvant prendre la forme d’American Depositary Shares, pour un montant total de 70,4 millions de dollars américains (soit 62,7 millions d’euros)
04/04/2019
Montrouge, France, le 4 avril (08h00 CEST), 2019 DBV Technologies annonce le prix de son offre globale d’actions ordinaires, pouvant prendre la forme d’American Depositary Shares, pour un montant total de 70,4 millions [...]

Pages